{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibrcrb2qfzmcuwhtufxe2nwwnvv5lvqvih3bgru42rpqvj46bgjhm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfssisf6vuc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/02/26/fda-lilly-obesity-gilead-hiv-sarepta/?utm_campaign=rss",
  "publishedAt": "2026-02-26T14:07:15.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared",
  "title": "STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more",
  "updatedAt": "2026-02-26T20:21:36.000Z"
}